- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00290069
Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
Comparative Study of Tacrolimus and Rapamycin to Evaluate the Renal Function in Patients Older Than 50 Years, Receptors of a Kidney From a Donor Older Than 55 Years in a Mycophenolate Mofetil and Daclizumab Immunosuppressor Regime
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study population characteristics raise the need to establish a treatment regime that assures suitable intensity immunosuppression to avoid the appearance of rejection episodes, but minimizes the doses to prevent over-immunosuppression in a population with a theoretic minor immune response.
On the other hand, the delay in the introduction of calcineurin inhibitors will prevent increasing the risk of early graft dysfunction allowing the highest post-transplant renal recovery in organs with less operative mass and greater sensibility to the nephrotoxic effect of these drugs.
The results of several studies confirm the goodness of regimes that include low doses of calcineurin inhibitors, delay their introduction or avoid them.
Nevertheless, although it is standard practice to evaluate the effectiveness of the regimes for a time to assure, with certainty, the response to the treatments, these follow-ups are still relatively short to assure the efficacy for a long-term study and to detect the problems. The studies with a high number of patients and long follow-up periods are difficult, so several authors have proposed different alternatives of control in a short-term study that could be useful as surrogate markers or predictive efficacy variables for the long term.
If the drug or study regime is efficient, the observed change after the transplantation surgery will have to be fast and objective. The increase of serum creatinine between 6 and 12 months post-transplant is a reliable marker of graft failure risk, and the magnitude of the serum creatinine change in these months is a marker of the relationship with long-term survival. For that reason, renal function (serum creatinine) is included as a main efficacy variable.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28034
- Hospital Universitario Ramon y Cajal
-
Contact:
- Roberto Marcén, MD
-
Principal Investigator:
- Roberto Marcén, MD
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Contact:
- José L Morales, MD
-
Principal Investigator:
- José L Morales, MD
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Contact:
- Fernando Anaya, MD
-
Principal Investigator:
- Fernando Anaya, MD
-
Santa Cruz de Tenerife, Spain, 38320
- Hospital Universitario de Canarias
-
Contact:
- Domingo Hernández, MD
-
Principal Investigator:
- Domingo Hernández, MD
-
Santander, Spain, 39008
- Hospital Universitario Marques de Valdecilla
-
Contact:
- Juan C Ruiz San Millán, MD
-
Principal Investigator:
- Juan C Ruiz San Millán, MD
-
Valencia, Spain, 46009
- Hospital Universitario La Fe
-
Contact:
- Jaime Sánchez Plumed, MD
-
Principal Investigator:
- Jaime Sánchez Plumed, MD
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Spain, 15706
- Complejo Hospitalario Universitario de Santiago
-
Contact:
- Rafael Romero, MD
-
Principal Investigator:
- Rafael Romero, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Both male and female patients older than 50 years who are primary recipients of a renal allograft from a donor older than 55 years.
- Patients who have given their consent previously to their participation in the study.
Exclusion Criteria:
- Recipients of a multi-organ transplant.
- Recipients of a transplant from a cadaveric donor with a cold ischemic time > 30 hours.
- Patients with a plasma renin activity (PRA) > 20% in 6 months previous to the inclusion.
- Breast-feeding, pregnant, or fertile women who do not use a reliable anticonceptive method before starting therapy with the study drug, during the therapy, and during the 4 months after the last dose of the drugs administered in the study.
- Patients with leukocyte count < 2.5 x 10^9/L, platelet count < 100 x 10^9/L, or haemoglobin < 6 g/dL in the inclusion time
- Patients with active hepatic illness evidence.
- Patients with active peptic ulcer.
- Patients with serious diarrhoea or any intestinal upset that may interfere in the absorption capability of oral medication, including diabetic patients with previously diagnosticated diabetic gastroenteropathy.
- Patients with evidence of active systemic infection that require the continued use of antibiotics or evidence of HIV infection or hepatitis B presence (positive HBs-Ag) or active chronic hepatitis C.
- Patients with malignancy history (except satisfactorily treated non- melanocytic localized skin cancer and cervix "in situ" carcinoma).
- Patients with history of psychologic disease that may interfere in the patients capability to understand the study requirements.
Patients who the investigator thinks need a treatment with any medication listed below:
- Azathioprine,
- Methotrexate,
- Cyclofosfamide,
- Polyclonal or monoclonal anti-lymphocitaries antibodies (OKT3, ATG), used for the induction in patients with high immunologic risk,
- Basiliximab, and
- Other research drugs
- Known hypersensibility or complete contraindication of any of the drugs administered in the study context or any other substance present in the study drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Serum creatinine at 6 months
|
Secondary Outcome Measures
Outcome Measure |
---|
Calculated creatinine clearance (Cockroft Gault)
|
Acute rejection rate at 6 months and time until first rejection
|
Patient and graft survival at 6 months
|
Rate and length of the delay in the graft function defined as dialysis in the first week post-transplant
|
Treatment failure at 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Miguel A Gonzalez Molina, MD, Sociedad Andaluza de Trasplantes de Organos y Tejidos
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Kidney Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Calcineurin Inhibitors
- Tacrolimus
- Sirolimus
Other Study ID Numbers
- SATOT42005
- EudraCT number: 2005-001854-25
- ALHAMBRA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
University of North Carolina, Chapel HillLantheus Medical ImagingCompletedChronic Kidney Diseases | Cystic Kidney DiseaseUnited States
-
SanofiTerminatedCongenital Cystic Kidney DiseaseGermany, Spain, United States, Australia, Belgium, Japan, Korea, Republic of, Netherlands
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Pang PengGuangdong Provincial Hospital of Traditional Chinese MedicineUnknownEnd-Stage Kidney Disease | Chronic Kidney FailureChina
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
George Washington UniversityCareDx; VirginiaBio Analytics, LLCTerminatedKidney Diseases | Kidney Failure, Chronic | Kidney Transplant Infection | Kidney Transplant Rejection | Kidney Injury | Kidney Disease, Chronic | Kidney Failure | Kidney Failure, Acute | Kidney Transplant; Complications | Kidney IschemiaUnited States
-
RenJi HospitalUnknownKidney Diseases,CysticChina
-
Renibus Therapeutics, Inc.CompletedKidney Failure, AcuteUnited States
-
Emory UniversityNorthwestern University; Columbia University; Satellite Healthcare; Norman S. Coplon...CompletedKidney Failure, Chronic | Kidney Transplantation | End-Stage Kidney DiseaseUnited States
Clinical Trials on Tacrolimus
-
Novartis PharmaceuticalsCompletedLiver Transplant RecipientBelgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
-
Novartis PharmaceuticalsCompletedLiver TransplantationUnited States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
-
Astellas Pharma IncAstellas Pharma Korea, Inc.CompletedLiver TransplantationKorea, Republic of
-
Heleen GrootjansChiesi Farmaceutici S.p.A.RecruitingLung Transplant; ComplicationsNetherlands
-
The Methodist Hospital Research InstituteVeloxis PharmaceuticalsWithdrawnAcute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
-
Taro Pharmaceuticals USACompleted
-
Peking Union Medical College HospitalUnknown
-
Technical University of MunichCompleted
-
Limerick BioPharmaCompleted
-
Panacea Biotec LtdCompleted